HomeNewsBusinessMarketsCipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings

Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings

Brokerages such as HSBC, Credit Suisse and Citi have downgraded the stock based on the company’s guidance ahead.

November 06, 2018 / 09:31 IST
Story continues below Advertisement
Employees and security staff work at the reception area of Cipla at its headquarters in Mumbai, India June 17, 2015. Cipla Ltd, India's fourth-largest drugmaker by sales, is planning to enter Latin America and Eastern Europe to tap into growing demand for generic drugs in emerging markets, Chief Executive Subhanu Saxena said. REUTERS/Danish Siddiqui - RTX1GUXV
Employees and security staff work at the reception area of Cipla at its headquarters in Mumbai, India June 17, 2015. Cipla Ltd, India's fourth-largest drugmaker by sales, is planning to enter Latin America and Eastern Europe to tap into growing demand for generic drugs in emerging markets, Chief Executive Subhanu Saxena said. REUTERS/Danish Siddiqui - RTX1GUXV

Moneycontrol News

Shares of Cipla traded lower by over 5 percent as investors continued to be bearish on the stock based on its results and tough guidance ahead.

Story continues below Advertisement

Brokerages such as HSBC, Credit Suisse and Citi have downgraded the stock based on the company’s guidance ahead.

Cipla reported a fall of 11 percent (year-on-year) in its net profit for the September quarter at Rs 377 crore. The company had reported a profit of Rs 422.9 during the same period of last year.